Adult patients with acute lymphoblastic leukaemia who experience relapsed or refractory disease have a poor prognosis. Inotuzumab ozogamicin (InO), an anti-CD22 antibody drug conjugate, could be a new option for treatment in these patients. At the EHA 2015 in Vienna, Dr. Daniel DeAngelo (Dana-Farber Cancer Institute, Boston) presented data from a phase III study comparing InO with standard of care (SOC).

(BELG J HEMATOL 2015;6(3):91–2)